<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03403556</url>
  </required_header>
  <id_info>
    <org_study_id>CREATE</org_study_id>
    <nct_id>NCT03403556</nct_id>
  </id_info>
  <brief_title>High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Multicenter, Open, Parallel, Phase 4 Study to Compare the Efficacy and Safety Between High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in High ASCVD Risk Patients With Type 2 diabEtes (CREATE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe compared to
      high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with
      type 2 diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to assess the efficacy and safety of Rosuvamibe® (rosuvastatin 10mg/ezetimibe
      10mg) vs. rosuvastatin 20mg treated for 24 weeks in atherosclerotic cardiovascular disease
      risk (≥ 7.5%) patients with type 2 diabetes
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change from baseline to week 24 in low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving &lt; 7.5% 10-year ASCVD risk without withdrawn due to adverse events</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to week 12 and to week 24 in 10-year ASCVD risk</measure>
    <time_frame>Up to 12 weeks, Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving the comprehensive lipid target (LDL-C &lt; 70mg/dL, Non-HDL-C &lt; 100mg/dL, and Apolipoprotein B &lt; 80mg/dL) without withdrawn due to adverse events</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to week 24 in calculated LDL cholesterol(mg/dL), HDL cholesterol(mg/dL), Triglyceride(mg/dL), non-HDL cholesterol(mg/dL), Apolipoprotein B(mg/dL), Apolipoprotein A1(mg/dL)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to week 24 in Hepatic Steatosis Index (HSI)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>hepatic steatosis index (HSI)= 8x(ALT/AST ratio)+BMI (+2, if female; +2, if diabetes mellitus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to week 24 in Fatty Liver Index (FLI)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>FLI scores will be calculated based on triglycerides, BMI, r-GT and Waist circumference. BMI(kg/m^2) will be calculated based on height(m) and weight(kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to week 24 in non-alcoholic fatty liver disease liver fat score (NAFLD-LFS)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to week 24 in HbA1c</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to week 24 in fasting plasma glucose (FPG)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to week 24 in sCD36</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to week 24 in HOMA-IR</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to week 24 in HOMA-B</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Rosuvamibe ® Tab.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 10mg/Ezetimibe10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monorova ® Tab.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvamibe</intervention_name>
    <description>Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks</description>
    <arm_group_label>Rosuvamibe ® Tab.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monorova</intervention_name>
    <description>Rosuvastatin 20mg qd for 24 weeks</description>
    <arm_group_label>Monorova ® Tab.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  ≥ 40 and &lt; 75 years of age at the time of informed consent

          -  Estimated 10-year ASCVD (atherosclerotic cardiovascular disease) risk ≥ 7.5% with type
             2 diabetes according to the American Diabetes Association criteria in screening

          -  HbA1c ≥ 6% and &lt; 10% in screening

          -  Body mass index (BMI) ≤ 35kg/m2 in screening

          -  Female of childbearing with a negative pregnancy test who must agree to use
             contraception (including those not medically pregnant) during the study period

          -  Written consent after being informed of the purpose and contents of the clinical trial
             and the characteristics and risks of IPs

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Chronic hepatitis B or chronic hepatitis C, severe hepatic dysfunction (AST, ALT, ALP
             or CPK ≥ 3 x ULN) in screening

          -  Heavy drinking &gt; 210g per week in screening

          -  Estimated GFR &lt; 30mL/min/1.73m2 using the CKD-EPI formula in screening

          -  Undergoing renal replacement therapy (hemodialysis or peritoneal dialysis) in
             screening

          -  Having used other statin (HMG-CoA converting enzyme inhibitors) than Rosuvastatin or
             fibrate drugs in the last 3 months before screening

          -  Taking any medication (ex. Fenofibrate, Omega 3 fatty acid, etc.) that may affect LDL

             * Can be enrolled after 4 week-washout

          -  Having used thiazolidinedione drugs in the last 3 months before screening

          -  Taking cyclosporine concomitantly

          -  Positive HIV test in screening

          -  Pregnant, breastfeeding, or childbearing women who are not likely to use the
             appropriate contraceptive methods as judged by investigator

          -  Subjects with a medical history of myopathy and rhabdomyolysis due to use of statin

          -  Hypersensitive to statin and ezetimibe

          -  Having endocrine or metabolic disease known to affect serum lipids or lipoproteins

               -  Uncontrolled diabetes (HbA1c ≥ 10%)

               -  Uncontrolled thyroid dysfunction (TSH ≥ 3 x ULN)

          -  Subjects with a medical history of acute arterial diseases such as unstable angina,
             myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary
             artery bypass graft or percutaneous coronary intervention in the last 6 months before
             screening

          -  Subjects with a surgical history of gastrointestine or drug absorption disorders due
             to gastrointestinal disorders

          -  Insulin-treated

          -  Taking other IPs in the last 30 days before screening

          -  Subjects who cannot discontinue contraindications that may affect the treatment of all
             types of diabetes and/or hypercholesterolemia during the study period

          -  Subjects with a significant or unstable medical or psychological condition that is
             judged by investigator to be detrimental to safety or to successful participation in
             the trial

          -  Other conditions than the above who is deemed to be ineligible to participate in the
             trial by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>February 25, 2018</last_update_submitted>
  <last_update_submitted_qc>February 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High ASCVD risk patients with type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

